^
Association details:
| Biomarker: | EGFR L747_A750delinsP |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Differential outcomes in patients with uncommon EGFR exon 19 mutations.
Published date:
05/16/2018
Excerpt:
Patients with the L747_A750 > P mutation demonstrated significantly worse PFS, DOT and OS than those with the E746_A750 and L747_P753 > S mutations...This study shows differential clinical outcome to EGFR-directed therapy within EGFR ex19 del tumors, specifically that pts with ex19 del L747_A750 > P have inferior outcomes versus those with E746_A750 or L747_P753 > S when treated with erlotinib.
DOI:
10.1200/JCO.2018.36.15_suppl.9056
